Lyell Immunopharma Inc
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells… Read more
Market Cap & Net Worth: Lyell Immunopharma Inc (LYEL)
Lyell Immunopharma Inc (NASDAQ:LYEL) has a market capitalization of $427.85 Million ($427.85 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13976 globally and #5698 in its home market, demonstrating a -21.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lyell Immunopharma Inc's stock price $20.14 by its total outstanding shares 21243954 (21.24 Million).
Lyell Immunopharma Inc Market Cap History: 2021 to 2026
Lyell Immunopharma Inc's market capitalization history from 2021 to 2026. Data shows growth from $164.43 Million to $427.85 Million (3.77% CAGR).
Index Memberships
Lyell Immunopharma Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #377 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1340 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.02% | #203 of 263 |
Weight: Lyell Immunopharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Lyell Immunopharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lyell Immunopharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
222.89x
Lyell Immunopharma Inc's market cap is 222.89 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $164.43 Million | $10.65 Million | -$250.22 Million | 15.44x | N/A |
| 2022 | $73.72 Million | $84.68 Million | -$183.12 Million | 0.87x | N/A |
| 2023 | $41.21 Million | $130.00K | -$234.63 Million | 317.03x | N/A |
| 2024 | $13.60 Million | $61.00K | -$342.99 Million | 222.89x | N/A |
Competitor Companies of LYEL by Market Capitalization
Companies near Lyell Immunopharma Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Lyell Immunopharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Lyell Immunopharma Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Lyell Immunopharma Inc's market cap moved from $164.43 Million to $ 427.85 Million, with a yearly change of 3.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $427.85 Million | -34.57% |
| 2025 | $653.89 Million | +4709.38% |
| 2024 | $13.60 Million | -67.01% |
| 2023 | $41.21 Million | -44.09% |
| 2022 | $73.72 Million | -55.17% |
| 2021 | $164.43 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Lyell Immunopharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $427.85 Million USD |
| MoneyControl | $427.85 Million USD |
| MarketWatch | $427.85 Million USD |
| marketcap.company | $427.85 Million USD |
| Reuters | $427.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.